Fundraising Fox
🦊/Companies
Sign in

miRagen Therapeutics

NASDAQ: VRDN

Boulder, US · Delaware corporation · 6 known investors

Find your way into miRagen Therapeutics

miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions. The company has advanced candidates in clinical testing and is preparing commercial infrastructure for potential product launches.

Biotech

Founders & leadership

WS
William S. MarshallFounder
JA
Jason A. LeveroneinExecutive
DR
David RodmanExecutive
SM
Stephen MahoneyPresident, Chief Executive Officer and Director
TB
Thomas BeethaminChief Operating OfficerExecutive Officer at Kiniksa
RT
Radhika TripuraneniinChief Medical Officer
SH
Seth HarmoninChief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
JT
Jennifer TousignantChief Legal Officer
CJ
Christopher J MorlNamed on SEC filing
CB
Christopher BowdenNamed on SEC filing
PD
Paul D. RubinNamed on SEC filing
JL
Joseph L. TunerNamed on SEC filing

Investors · 6

Brace PharmaAtlanta
MC Healthcare VenturesCambridge
Atlas VenturereportedCambridge · $500K – $1M
Boulder Venturesreported · 2 sourcesBoulder · $1M – $4Mvia Kyle Lefkoff · board
HeartlandreportedBrande
Remeditex VenturesreportedDallas

Reported raises · per SEC filings

Form D private placements

$185.8M disclosed across 8 rounds · 2010–2020

▶$91MraisedNov 2020 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joesph L. TurnerDirector
  • Jonathan ViolinExecutive Officer
  • Lee M RauchExecutive Officer, Director
  • Jason A. LeveroneExecutive Officer
  • Diana EscolarExecutive Officer
  • Jeffrey S HatfieldDirector
  • Peter E. HarwinDirector
  • Tomas KiselakDirector
  • Arlene M. MorrisDirector
Offering amount
$91M
Amount sold
$91M
Finders' fees
$4.5M
Placement agents
Jefferies LLC, JMP Securities LLC
First sale
Oct 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedOct 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William S. MarshallExecutive Officer, Director
  • Jason A. LeveroneExecutive Officer
  • Joseph L. TurnerDirector
  • Arlene M. MorrisDirector
  • Kevin KochDirector
  • Thomas E. HughesDirector
  • Jeffrey S. HatfieldDirector
  • Christopher BowdenDirector
  • Paul D. RubinExecutive Officer
Offering amount
$5M
Amount sold
$1.5M
First sale
Aug 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$172.3KraisedNov 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jason A. LeveroneExecutive Officer
  • Christopher BowdenDirector
  • Paul D. RubinExecutive Officer
  • Joseph L. TunerDirector
  • Jeffrey S. HatfieldDirector
  • Bruce L. BoothDirector
  • Adam S. LevyExecutive Officer
  • Thomas E. HughesDirector
  • William S. MarshallExecutive Officer, Director
  • Kevin KochDirector
Offering amount
$172.3K
Amount sold
$172.3K
First sale
Nov 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40.7MraisedFeb 2017 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John W. CreecyDirector
  • Jason A LeveroneExecutive Officer
  • Kevin KochDirector
  • Thomas E. HughesDirector
  • William S. MarshallExecutive Officer, Director
  • Adam S LevyExecutive Officer
  • Kyle A. LefkoffDirector
  • Bruce L. BoothDirector
  • Paul D. RubinExecutive Officer
Offering amount
$40.7M
Amount sold
$40.7M
Sales commissions
$1.2M
Placement agents
Wedbush Securities Inc.
First sale
Feb 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedNov 2015 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas E HughesDirector
  • Kyle LefkoffDirector
  • Marvin H CaruthersDirector
  • David RodmanExecutive Officer
  • William S. MarshallExecutive Officer, Director
  • Joshua ResnickDirector
  • John CreecyDirector
  • Jason A LeveroneExecutive Officer
  • Bruce L BoothExecutive Officer, Director
  • Christopher J MorlExecutive Officer
Offering amount
$41.1M
Amount sold
$25M
First sale
Oct 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.5MraisedFeb 2015 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas HughesDirector
  • Marvin CaruthersDirector
  • Kyle LefkoffDirector
  • Christopher J MorlExecutive Officer
  • Bruce BoothExecutive Officer, Director
  • Jason A LeveroneExecutive Officer
  • David RodmanExecutive Officer
  • John CreecyDirector
  • William S. MarshallExecutive Officer, Director
Offering amount
$20M
Amount sold
$8.5M
First sale
Feb 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13MraisedJun 2014 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce BoothDirector
  • John CreecyDirector
  • Kyle LefkoffDirector
  • William S. MarshallExecutive Officer, Director
  • Marvin CaruthersDirector
  • Jason LeveroneExecutive Officer
  • David M. RodmanExecutive Officer
  • Thomas HughesDirector
  • Christopher J MorlExecutive Officer
Offering amount
$20M
Amount sold
$13M
First sale
Apr 2012
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedJan 2012 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce BoothExecutive Officer, Director
  • Jason LeveroneExecutive Officer
  • Thomas HughesDirector
  • Marvin CaruthersDirector
  • Kyle LefkoffDirector
  • William S. MarshallExecutive Officer, Director
Offering amount
$6M
Amount sold
$6M
First sale
Sep 2010
Incorporated
Corporation, Delaware
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$19.7Mvaluation at IPOFeb 2015 · $2.80/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

miRagen Therapeutics Secures $41 million Series C Financing to Advance Two MicroRNA Programs into Clinical Trials | Business Wirebusinesswire.com · Nov 2015miRagen Therapeutics Raises $41M in Series C Funding - FinSMEsfinsmes.com · Nov 2015Boulder’s miRagen raises $20M to boost pipelinedailycamera.com · Apr 2012

Frequently asked questions

What does miRagen Therapeutics do?
miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions. The company has advanced candidates in clinical testing and is preparing commercial infrastructure for potential product launches.
Who founded miRagen Therapeutics?
miRagen Therapeutics was founded by William S. Marshall.
Who are miRagen Therapeutics's investors?
miRagen Therapeutics's investors include Brace Pharma, MC Healthcare Ventures, Atlas Venture, Boulder Ventures, Heartland, Remeditex Ventures.
How much funding has miRagen Therapeutics raised?
miRagen Therapeutics has disclosed $185.8M raised across 8 rounds.
Where is miRagen Therapeutics headquartered?
miRagen Therapeutics is headquartered in Boulder, US.